ACIU
Ac Immune Sa
NASDAQ · Biotechnology
$3.14
+0.18 (+6.08%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 116.52M | 119.79M | 119.57M |
| Net Income | 209.8K | 199.8K | 200.3K |
| EPS | — | — | — |
| Profit Margin | 0.2% | 0.2% | 0.2% |
| Rev Growth | +18.7% | -0.9% | +8.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 133.57M | 114.17M | 132.63M |
| Total Equity | 185.53M | 166.00M | 182.25M |
| D/E Ratio | 0.72 | 0.69 | 0.73 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 267.6K | 316.5K | 305.4K |
| Free Cash Flow | 236.0K | 248.3K | 178.6K |